Abdul-Hamid Abed Bazarbachi, MD
Hematology/Oncology
Blood and Marrow Stem Cell Transplantation, Hematology, Medical Oncology
On the web
Overview
Dr. Bazarbachi is an Assistant Professor of Medicine at Columbia University Irving Medical Center in the Blood and Marrow Transplantation and Cell Therapy Program.
He received his medical degree from the American University of Beirut in Beirut, earned an inter-university diploma in allogeneic hematopoietic stem cell transplantation at Sorbonne University in Paris, and completed a research fellowship at Dana-Farber Cancer Institute in Boston. He completed his internal medicine residency at NYC Health + Hospitals/Jacobi Medical Center in the Bronx, and his hematology and oncology fellowship at NewYork-Presbyterian/Columbia University Irving Medical Center in New York City. Dr. Bazarbachi specializes in blood and marrow transplantation and cellular therapy.
Areas of Expertise / Conditions Treated
- Allogeneic Stem Cell Transplant
- Amyloidosis
- Autologous Stem Cell Transplant
- Bone Marrow Transplant
- Cellular Therapy
- Leukemia
- Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Myelofibrosis
- Myeloproliferative Neoplasms
Academic Appointments
- Assistant Professor of Medicine at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Languages
- Arabic
- English
- French
Gender
- Male
Schedule an Appointment
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
161 Fort Washington Avenue
New York, NY 10032
Phone:
Fax:
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Student Health
Affinity Health Plan
- Essential Plan
- Medicaid Managed Care
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- POS
- PPO
ElderServe
- Special Needs
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Individual Network (Exchange)
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Healthspring (Cigna Medicare)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
UnitedHealthcare
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
*Before your appointment, please contact the doctor’s office or your insurance provider to verify that your insurance is accepted. This list of insurances can change, and the insurance plans listed may not be accepted at all office locations for this provider.
Credentials & Experience
Education & Training
- MD, American University of Beirut, Beirut, Lebanon
- Inter-University Diploma (DIU), Allogeneic Hematopoietic Stem Cell Transplantation, Sorbonne University, Paris, France
- Residency: Internal Medicine, NYC Health + Hospitals / Jacobi Medical Center, Bronx, NY
- Fellowship: Hematology and Oncology, NewYork-Presbyterian / Columbia University Irving Medical Center, New York, NY
- Fellowship: Research, Dana-Farber Cancer Institute, Boston, MA
Committees, Societies, Councils
- American Society of Hematology
- American Society of Clinical Oncology
- American Society for Transplantation and Cellular Therapy
- European Society for Blood and Marrow Transplantation
Board Certifications
- Medical Oncology
- Hematology
Honors & Awards
- 2025: Young Investigator Award, Conquer Cancer, the ASCO Foundation
- 2022: Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award, American Society of Hematology
Research
Dr. Bazarbachi’s research focuses on improving transplantation outcomes and understanding mechanisms of response and resistance to cellular therapy and immunotherapy, particularly in multiple myeloma and AL amyloidosis.
Selected Publications
- Bazarbachi AH, Lentzsch S, Facon T, Harousseau JL, Mohty M. Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making. Journal of Clinical Oncology. Published online September 10, 2026. doi:10.1200/JCO-26-00545
- Mellgard GS, Bazarbachi AH, Zanwar S, et al. Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients. American Journal of Hematology. 2026;101(4):768–783. Mellgard and Bazarbachi contributed equally. doi:10.1002/ajh.70257
- Bazarbachi AH, Bhutani D, Hughes MS, et al. CAR T-cells in multiple myeloma: the race to the start line. Bone Marrow Transplantation. 2026;61:260–274. doi:10.1038/s41409-025-02787-9
- Bazarbachi AH, Zanwar S, Hegenbart U, et al. Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era. HemaSphere. 2025;9(12):e70276. doi:10.1002/hem3.70276
- Bazarbachi AH, Labopin M, Raiola AM, et al. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. 2024;130(18):3123–3136. doi:10.1002/cncr.35365
- Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pregerminal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021;138(20):1980–1985. doi:10.1182/blood.2021011452
- Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Communications. 2021;12:868. doi:10.1038/s41467-021-21177-5
For a complete list of publications, please visit PubMed.gov